- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1746 |
Product Name |
ADT1746-Human Anti-CD3ExBCMA Bispecific Antibody |
Isotype |
Human IgG2-kappa |
Clonity |
Monoclonal |
|
Alternate Names Human Anti-CD3E mAb, Anti-CD3E Monoclonal Antibody, CD3E recombinant antibody, Anti-CD3E Bispecific Antibody, Human Anti-BCMA mAb, BCMA recombinant antibody, Anti-BCMA Monoclonal Antibody, Anti-BCMA Bispecific Antibody |
|
Official Symbol |
CD3ExBCMA |
Target 1 |
CD3E |
Gene ID 1 |
916 |
Target 2 |
BCMA |
Gene ID 2 |
608 |
Species |
Human |
Drug Name |
Elranatamab |
Endotoxin |
<1EU/mg. Determined by the LAL method. |
Sterility |
0.2 μM filtered. |
Expression Host |
CHO Cells |
CAS Number |
2408850-14-4 |
Chemical Formula |
C6440H9958N1738O2010S49 |
Molecular Weight |
148.5 KDa |
Product Description |
Elranatamab is a bispecific antibody used to treat adults with relapsed or refractory multiple myeloma. |
Mechanism of Action |
BCMA is a B cell maturation antigen that binds several ligands to activate various survival signalling pathways, including NF-kappa B, STAT3, ERK1/2, and AKT/PI3K signalling pathways. It is often overexpressed in malignant plasma B cells, including multiple myeloma cells, making it a promising therapeutic target for T-cell engaging antibodies.
Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed T-cell engaging antibody.It binds BCMA on plasma cells, plasmablasts, and multiple myeloma cells and CD3 on T-cells leading to cytolysis of the BCMA-expressing cells. Elranatamab activated T-cells, caused pro-inflammatory cytokine release, and resulted in multiple myeloma cell lysis.
|
Metabolism |
Elranatamab is expected to be metabolized into small peptides by catabolic pathways. |
Size |
1mg,5mg,50mg,100mg |
Research Area |
Cancer |
Application |
FuncS |
Purity |
>90% |
Concentration |
Batch dependent |
Buffer |
Supplied in PBS, pH 7.4,Contains no stabilizers or preservatives |
Recommended Dilution Buffer |
ABDB-1002 or PBS, pH 7.4, Contains no stabilizers or preservatives. |
Storage |
2 weeks, 2-8℃ under sterile conditions after reconstitution. Avoid repeated freeze-thaw. -80°C for one-year storage. |
Shipping Condition |
Shipped on ice packs. |
Protocol Information |
Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose-response or titration experiment. |
Note |
For Research Use Only! |
|
Reference 1. Grosicki S, Bednarczyk M, Kociszewska K: Elranatamab: a new promising BispAb in multiple myeloma treatment. Expert Rev Anticancer Ther. 2023 Jul 20:1-8. doi: 10.1080/14737140.2023.2236303.
2. Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, Rodriotaguez-Otero P, Martinez-Lopez J, Koehne G, Touzeau C, Jethava Y, Quach H, Depaus J, Yokoyama H, Gabayan AE, Stevens DA, Nooka AK, Manier S, Raje N, Iida S, Raab MS, Searle E, Leip E, Sullivan ST, Conte U, Elmeliegy M, Czibere A, Viqueira A, Mohty M: Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023 Aug 15. doi: 10.1038/s41591-023-02528-9.
|
FAQ
-
+ -
What is a T-cell engager bispecific antibody?
T-cell engagers (e.g., Blinatumomab) bind CD3 on T-cells and a tumor antigen (e.g., CD19), redirecting T-cells to kill cancer cells without MHC restriction.
-
+ -
How can I obtain COA of the reagent that I received?
Please contact us via email info@alphalifetech.com for detailed information about the product.
-
+ -
What is BCMA?
B-cell maturation antigen (BCMA) is highly expressed in multiple myeloma cells, making it a key therapeutic target. -
+ -
What are the advantages of bispecific antibodies?
Dual targeting reduces resistance, enhances specificity, lowers systemic toxicity, and enables novel mechanisms (e.g., immune cell recruitment or receptor co-inhibition).